Defining the clinical course of multiple sclerosis: The 2013 revisions

By F. Jacques. Neurology, 2015

1,588 citations recorded by the source corpus.

I read with interest the article by Lublin et al.1 When defining disease subtypes—like neuromyelitis optica—it is clear that pathophysiology should take precedence over clinical and subjective descriptions. The subtypes proposed by Lublin et al. are arbitrary and often diagnosed retrospectively. …

Subfields: Neurology, Pathology and Forensic Medicine, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/3850ac746353bf6239f358cbd244019fa99c7cd3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. B. Cree
2. Stephen L. Hauser
3. G. Giovannoni
4. Ruth Dobson

In Pathology and Forensic Medicine

1. B. Cree
2. Stephen L. Hauser
3. G. Giovannoni
4. Ruth Dobson

In Psychiatry and Mental health

1. B. Cree
2. Stephen L. Hauser
3. G. Giovannoni
4. Ruth Dobson

Citations in the corpus

• Treatment of Multiple Sclerosis: A Review. (2020, background): “(3) Slowly enlarging lesions due to gradual concentric expansion of chronic plaques, characterized by a rim of activated microglia at the leading edge, astrocytosis, stressed oligodendrocytes and progressive axonal injury.”
• Multiple sclerosis – a review (2018, positive): “Given the above, MS can be thought of as a single disease existing within a spectrum extending from relapsing (“inflammatory dominant”) to progressive (“neurodegeneration dominant”), in keeping with the 2013 revisions to the clinical course of MS [48].”
• Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice (2017, background): “preponderance, age distribution, age at onset, and distribution of clinical subtypes [RR MS, secondary progressive MS, primary progressive MS, and clinically isolated syndrome (CIS)] (Table 1) (12).”